Telomir Pharmaceuticals Reports Telomir-1 Resets DNA Methylation Of Tumor Suppressor Genes Implicated In Two Of The Most Persistent Challenges In Oncology, Metastasis And Treatment Resistance

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology—Metastasis and Treatment Resistance

Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A — genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models.

On October 6, 2025, Telomir Pharmaceuticals, Inc. (the "Company") announced new cancer results from preclinical studies of its lead investigational compound, Telomir-1, in aggressive prostate cancer models.

The studies demonstrated that Telomir-1 resets abnormal DNA methylation to restore the function of two additional critical tumor suppressor genes — MASPIN and RASSF1A. Both genes are frequently silenced in cancer, a change that is closely linked to metastasis and treatment resistance, two of the most significant challenges in oncology.

MASPIN is a natural defense protein that blocks tumor invasion, regulates cell migration and angiogenesis, promotes apoptosis, and enhances treatment sensitivity. In an aggressive prostate-cancer model in vivo, MASPIN was silenced by DNA hypermethylation. Telomir-1 reversed the chemotherapy-induced DNA methylation to restore MASPIN activity, consistent with reactivation of this key tumor-suppressor pathway.

RASSF1A is a critical regulator of cell cycle brakes, apoptosis, and suppression of metastasis. It is commonly silenced in aggressive cancers by hypermethylation. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy.

By reactivating MASPIN and RASSF1A through DNA methylation reset, Telomir-1 expands the potential to restore natural tumor defenses, counteract chemotherapy-induced resistance, and help limit cancer metastasis.

The Company is continuing its preclinical development of Telomir-1 and is currently advancing the program with IND-enabling studies.